Fig. 6.

B cells are partially responsible for dMP MOG treatment efficacy. (A) Comparison of the cumulative score normalized by the number of days post–treatment initiation in EAE C57BL6 and EAE MuMt^−/− mice administered with dMP OVA. (B) EAE score curve and cumulative scores following treatment initiated at a score of 3 in MuMt^−/− mice as in Fig. 1B, with a second injection 3 d later. (C) Comparison of cumulative score normalized by the number of days post–treatment initiation in C57BL6 and MuMt^−/− mice administered with dMP MOG. n= 5 to 9 per group and represents 2 independent experiments; *P < 0.05.